Skip to main content
SpringerLink
Log in

Graft versus leukemia

  • Graft Versus Leukemia
  • Published:
Immunologic Research Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Barrett AJ, Horowitz MM, Gale RP, Biggs JC, Camitta BM, Dicke KA, Gluckman E, Good RA, Herzig RH, Lee MB: Marrow transplantation for acute lymphoblastic leukemia: Factors affecting relapse and survival. Blood 1989;74:862–871.

    PubMed  CAS  Google Scholar 

  2. Santos GW: Marrow transplantation in acute non lymphocytic leukemia. Blood 1989;74:901–908.

    PubMed  CAS  Google Scholar 

  3. Thomas ED, Clift RA: Indications for marrow transplantation in chronic myelogenous leukemia. Blood 1989;73:861–864.

    PubMed  CAS  Google Scholar 

  4. Gale RP: Graft versus host disease. Immunol Rev 1986;88:193–214.

    Article  Google Scholar 

  5. Barnes DWH, Corp MJ, Loutit LF, Neal FE: Treatment of murine leukemia with X-rays and homologous bone marrow. Br Med J 1956;ii:626–627.

    Article  Google Scholar 

  6. Okunewick JP, Meredith RP: Graft-versus-Leukemia in Man and Animal Models. Boca Raton, CRC Press, 1989.

    Google Scholar 

  7. Bortin MM, Truitt RL, Rimm AA, Bach FH: Graft versus leukemia activity induced by alloimmunization without augmentation of graft versus host activity. Nature 1979;281:490–491.

    Article  PubMed  CAS  Google Scholar 

  8. Butturini A, Bortin MM, Gale RP: Graft-versus-leukemia following bone marrow transplantation. Bone Marrow Transplant 1987;2:233–242.

    PubMed  CAS  Google Scholar 

  9. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B: Graft-versus-leukemia reaction after bone marrow transplantation. Blood 1990;75:555–562.

    PubMed  CAS  Google Scholar 

  10. Butturini A, Gale RP: The role of T cells in preventing relapse in chronic myelogenous leukemia. Bone Marrow Transplant 1987;2:351–354.

    PubMed  CAS  Google Scholar 

  11. Gale RP, Horowitz MM, Bortin MM: Identical twin transplants for leukemia. Blood 1990;76(suppl 1):540a.

    Google Scholar 

  12. Backman L, Ringden O, Tollemar J, Lonnqvist B: An increased risk of relapse in cyclosporin-treated patients: Long-term follow-up of a randomized trial. Bone Marrow Transplant 1988;3:463–471.

    PubMed  CAS  Google Scholar 

  13. Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L, Buckner CD, Anasetti C, Appelbaum FR, Badger C: Influence of acute and chronic graft versus host disease on relapse and survival after bone marrow transplantation for HLA identical siblings as treatment of acute and chronic leukemia. Blood 1989;73:1720–1728.

    PubMed  CAS  Google Scholar 

  14. Hale G, Cobbald S, Waldmann H, for Campath-1 users: T-cell depletion with Campath-1 in allogeneic bone marrow transplantation. Transplantation 1988;45:753–759.

    Article  PubMed  CAS  Google Scholar 

  15. Marmont AM, Horowitz MM, Gale RP, Ash RC, van Bekkum DW, Champlin RE, Dicke KA, Goldman JM, Good RA, Herzig RH, Hong R, Masaoka T, O'Reilly RJ, Prentice HG, Rimm AA, Ringden O, Speck B, Weiner RS, Bortin MM: T-cell depletion of HLA-identical transplants in leukemia. Blood 1991;78:2120–2130.

    PubMed  CAS  Google Scholar 

  16. International Bone Marrow Transplant Registry: Effect of methotrexate on relapse after bone marrow transplantation for acute lymphoblastic leukemia. Lancet 1989;i:535–537.

    Google Scholar 

  17. Truitt RL, Shih CY, Lefever AV, Tempelis LD, Andreani M, Bortin MM: Characterization of alloimmunization-induced T lymphocytes reactive against AKR leukemia in vitro and correlation with graft-vs-leukemia activity in vivo. J Immunol 1983;131:2050–2058.

    PubMed  CAS  Google Scholar 

  18. Hercend T, Takvorian T, Nowill A, Tantravahi R, Moingeon P, Anderson KC, Murray C, Bohuon C, Ythier A, Ritz J: Characterization of natural killer cells with antileukemia activity following allogeneic bone marrow transplantation. Blood 1986;67:722–728.

    PubMed  CAS  Google Scholar 

  19. Hauch M, Gazzola MV, Small T, Bordignon C, Barnett L, Cunningham I, Castro-Malaspinia H, O'Reilly RJ, Keever CA: Antileukemia potential of interleukin-2 activated natural killer after bone marrow transplantation for chronic myelogenous leukemia. Blood 1990;75:2250–2262.

    PubMed  CAS  Google Scholar 

  20. MacKinnon S, Hows JM, Goldman JM: Induction of in vitro antileukemia activity following bone marrow transplantation for chronic myeloid leukemia. Blood 1990;76:2037–2045.

    PubMed  CAS  Google Scholar 

  21. Butturini A, Bonilauri E, Izzi GC: Therapy of advanced acute myeloblastic leukemia with cytarabine and interleukin-2. Leuk Res 1991; 15:759–763.

    Article  PubMed  CAS  Google Scholar 

  22. Sosman JA, Oettel KR, Smith SD, Hank JA, Fisch P, Sondel OM: Specific recognition of human leukemic cells by allogeneic T cells. II. Evidence for HLA-DR restricted determinants on leukemia cells that are cross reactive with determinants present on unrelated on leukemia cells. Blood 1990;75:2005–2016.

    PubMed  CAS  Google Scholar 

  23. Leventhal EB, Halterman RH, Rosenberg EB, Herberman RB: Immune reactivity of leukemia patients to autologous blast cells. Cancer Res 1972;32:1820–1825.

    PubMed  CAS  Google Scholar 

  24. Rosenberg EB, Herberman RB, Levine PH, Halterman RH, McCoy JL, Wunderlich JR: Lymphocyte cytotoxicity reactions to leukemia associated antigens in identical twins. Int J Cancer 1972;9:648–658.

    Article  PubMed  CAS  Google Scholar 

  25. Yssel H, Spits H, de Vries JE: A cloned human T cell line cytotoxic for autologous and allogeneic B lymphoma cells. J Exp Med 1984;160:239–254.

    Article  PubMed  CAS  Google Scholar 

  26. Bensussan A, Lagabrielle JF, Degos L: TCR gamma/delta bearing lymphocyte clones with lymphokine-activated killer activity against autologous leukemia cells. Blood 1989;73:2077–2080.

    PubMed  CAS  Google Scholar 

  27. Fisch P, Weil-Hillman G, Upperkamp M, Hank JA, Chen BP, Sosman JA, Bridges A, Colamonici OR, Sondel PM: Antigen-specific recognition of autologous leukemia cells and allogeneic class I MHC antigens by IL2-activated cytotoxic T cells from a patient with acute T cell leukemia. Blood 1989;74:343–353.

    PubMed  CAS  Google Scholar 

  28. Adler A, Albo V, Blatt J, Whiteside TL, Herberman RB: Interleukin-2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. II. Feasibility of LAK generation in children with active disease in remission. Blood 1989;74:1690–1697.

    PubMed  CAS  Google Scholar 

  29. Zhou M, Findley HW, Davis R, Ragab AH: Assay of lymphokine-activated killer activity generated from bone marrow cells of children with acute lymphoblastic leukemia. Blood 1990;75:160–165.

    PubMed  CAS  Google Scholar 

  30. Perreault C, Deary F, Brochu S, Gyger M, Belanger R, Roy D: Minor histocompatibility antigens. Blood 1990;76:1269–1280.

    PubMed  CAS  Google Scholar 

  31. Van Els CACM, Bakker A, Zwinderman AH, Zwaan FF, van Rood JJ, Goulmy E: Effector mechanisms in graft versus host disease in response to minor histocompatibility antigens. I. Absence of correlation with cytotoxic effector cells. Transplantation 1990;50:62–66.

    PubMed  Google Scholar 

  32. Van Els CACM, Bakker A, Zwinderman AH, Zwaan FF, van Rood JJ, Goulmy E: Effector mechanisms in graft versus host disease in response to minor histocompatibility antigens. II. Evidence of a possible involvement of proliferative T cells. Transplantation 1990;50:67–61.

    PubMed  Google Scholar 

  33. Marrack P, Kappler J: T cells can distinguish between allogeneic major histocompatibility complex products on different cell types. Nature 1988;322:840–843.

    Article  Google Scholar 

  34. Heath WR, Hurd ME, Carbone FR, Sherman LA: Peptide-dependent recognition of H-2kb by alloreactive cytotoxic T lymphocytes. Nature 1989;341:749–752.

    Article  PubMed  CAS  Google Scholar 

  35. Nepom GT: The effects of variations in human immune response genes. N Engl J Med 1989;321:751–752.

    PubMed  CAS  Google Scholar 

  36. Clayberger C, Wright A, Medeiros LJ, Koller TD, Link MP, Smith SD, Warnke RA, Krensky AM: Absence of cell surface LFA-1 as a mechanism of escape from immunosurveillance. Lancet 1987;ii:533–536.

    Article  Google Scholar 

  37. Foon KA: Biological response modifiers: The new immunotherapy. Cancer Res 1989;49:1621–1639.

    PubMed  CAS  Google Scholar 

  38. Cohen J: Cytokines as mediators of graft versus host disease. Bone Marrow Transplant 1988;3:193–197.

    PubMed  CAS  Google Scholar 

  39. Holler E, Kolb HJ, Moller A, Kempeni J, Liesenfeld S, Pechumer H, Lehmacher W, Ruckdeschel G, Gleixner B, Riedner C, Ledderose G, Brehm G, Mittermüller J, Wilmanns W: Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 1990;75:1011–1016.

    PubMed  CAS  Google Scholar 

  40. Cleveland MG, Lane G, Klimpel GR: Enhanced interferon a/b (IFN a/b) and defective IFN g production in chronic graft versus host disease: A potential mechanism for immunosuppression. Cell Immunol 1987; 110:120–130.

    Article  PubMed  CAS  Google Scholar 

  41. Duncombe AS, Meager A, Prentice HG: γ-Interferon and tumor necrosis factor production after bone marrow transplantation is augmented by exposure to marrow fibroblasts infected with cytomegaloviurs. Blood 1990;76:1046–1053.

    PubMed  CAS  Google Scholar 

  42. Hale G, Cobbold S, Waldmann H, for Campath Users: T cell depletion with Campath 1 in allogeneic bone marrow transplantation. Transplantation 1988;45:735–739.

    Article  Google Scholar 

  43. Gressler VH, Weinkanf RE, Franklin WA, Golomb HH: Modulation of the expression of major histocompatibility antigens on splenic hairy cells. Differential effect upon in vitro treatment with alpha 2b interferon, gamma interferon and interleukin-2. Blood 1988;72:1042–1053.

    Google Scholar 

  44. Sullivan KM, Deeg JH, Sanders J, Klosterman A, Amos D, Shulman H, Sale G, Martin P, Witherspoon R, Appelbaum FR: Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic bone marrow transplantation. Blood 1986;67:1172–1175.

    PubMed  CAS  Google Scholar 

  45. Sullivan KM, Storb R, Buckner CD, Fefer A, Fisher I, Weiden PL, Witherspoon RP, Appelbaum FR, Bnaji M, Hansen J: Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematological neoplasms. N Engl J Med 1989; 320:828–834.

    PubMed  CAS  Google Scholar 

  46. Odom LF, August CS, Githens JH, Humbert JR, Morse H, Peakman D, Sharma B, Rusnak SL, Johnson FB: Remission of relapsed leukemia during a graft versus host reaction: A ‘graft versus leukemia’ reaction in man? Lancet 1978;ii:537–540.

    Article  Google Scholar 

  47. Singer JW, Keating A, Ramberg R, McGuffin R, Sanders JE, Sale G, Fialkow PJ, Thomas ED: Long-term stable hematopoietic chimerism following marrow transplantation for acute lymphoblastic leukemia: A case report with in vitro marrow culture studies. Blood 1983;62:869–872.

    PubMed  CAS  Google Scholar 

  48. Sullivan KM, Shulman H: Cyclosporine and long-term follow-up care of the marrow transplant recipients: Clinical histories of chronic graft versus host disease, obliterative bronchiolitis and graft versus leukemia effect. Transplant Proc 1989;21(suppl 1):51–62.

    PubMed  CAS  Google Scholar 

  49. Higano CS, Brixley M, Bryant E, Durnam DM, Doney K, Sullivan KM, Singer JW: Durable complete remission of acute non lymphocytic leukemia associated with discontinuation of immune suppression following relapse after allogeneic bone marrow transplantation. A care report of a probable graft versus leukemia effect. Transplantation 1990; 50:175–177.

    Article  PubMed  CAS  Google Scholar 

  50. Frassoni F, Sessarego M, Bacigalupo A, Strada P, Repetto M, Miceli S, Occhini D, Defferrari R, Marmont A: Competition between recipient and donor cells after bone marrow transplantation for chronic myelogenous leukemia. Br J Haematol 1988;69:471–475.

    Article  PubMed  CAS  Google Scholar 

  51. Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990;76:2462–2465.

    PubMed  CAS  Google Scholar 

  52. Jones RJ, Vogelsang GB, Hess AD, Farmer ER, Mann RB, Geller RB, Piantadosi S, Santos GW: Induction of graft-versus-host disease after autologous bone marrow transplantation. Lancet 1989;i:754–757.

    Article  Google Scholar 

  53. Talbot DC, Powles RL, Sloane JP, Rose J, Treleaven J, Aboud H, Helenglass G, Parikh P, Smith C, Rowley M: Cyclosporine-induced graft versus host disease following autologous bone marrow transplantation in acute myelogenous leukemia. Bone Marrow Transplant 1990;6:17–20.

    PubMed  CAS  Google Scholar 

  54. Chow LH, Mosbach-Ozmen L, Ryffel B, Borel JF: Syngeneic graftversus-host disease induced by cyclosporin: A reappraisal. Transplantation 1988;46:107S-112S.

    Article  PubMed  CAS  Google Scholar 

  55. Geller RB, Esa AH, Beschorner WE, Frondora CG, Santos GW, Hess AD: Successful in vitro graft-versustumor effect against an Ia bearing tumor using cyclosporine-induced syngeneic graft-versus-host disease in the rat. Blood 1987;74:1165–1171.

    Google Scholar 

  56. Meyers JD, Flournoy N, Sanders JE, McGuffin RW, Newton BA, Fisher LD, Lum LG, Appelbaum FR, Doney K, Sullivan KM: Prophylactic use of human leukocyte interferon after allogeneic marrow transplantation. Ann Intern Med 1987; 107:809–816.

    PubMed  CAS  Google Scholar 

  57. Gottlieb DJ, Brenner MK, Heslop HE, Bianchi AC, Bello-Fernandez C, Mehta AB, Newland AC, Galazka AR, Scott EM, Hoffband AV: A phase I clinical trial of recombinant interleukin 2 following high dose chemo-radiotherapy for haematological malignancies: Applicability to the elimination of minimal residual disease. Br J Cancer 1989; 60:610–615.

    PubMed  CAS  Google Scholar 

  58. Blaise D, Olive D, Stoppa AM, Viens P, Pourreau C, Lopez G, Attal M, Jasmin C, Monges G, Mawas C: Hematologic and immunologic effects of the systemic administration of recombinant interleukin 2 after autologous bone marrow transplantation. Blood 1990;76:1092–1097.

    PubMed  CAS  Google Scholar 

  59. Meloni G, Foa R, Vignetti M, et al: ABMT followed by IL-2 in children with advanced leukemia (Abstract). 17th Annu Meet EBMT, Cortina d'Ampezzo, 1991, p 27.

  60. Arcese W, Mauro FR, Alimena G, LoCoco F, DeCuia MR, Screnci M, Iori AP, Montefusco E, Mandelli F: Interferon therapy for Ph1 positive CML patients relapsing after T cell depleted allogeneic bone marrow transplantation. Bone Marrow Transplant 1990;5:309–315.

    PubMed  CAS  Google Scholar 

  61. Higano CS, Raskin W, Durnam D, Singer JW: Interferon α (IF) induces cytogenetic remissions in patients who relapse with chronic myelogenous leukemia (CML) after allogeneic BMT (Abstract). Exp Hematol 1990;6:645.

    Google Scholar 

  62. Ashwell JD, Longo DL, Bridges SH: T cell tumor elimination as a result of T cell receptor mediated activation. Science 1987;237:61–64.

    Article  PubMed  CAS  Google Scholar 

  63. Shi Y, Sahai BM, Green DR: Cyclosporine A inhibits activation-induced cell death in T cell hybridomas and thymocytes. Nature 1989; 339:625–626.

    Article  PubMed  CAS  Google Scholar 

  64. Lotem I, Sachs J: In vitro control of differentiation of myeloid leukemia cells by cyclosporine and recombinant interleukin-1 alpha. Blood 1988;72:1595–1601.

    PubMed  CAS  Google Scholar 

  65. Butturini A, Gale RP: How can we cure leukemia. Br J Haematol 1989; 72:479–485.

    Article  PubMed  CAS  Google Scholar 

  66. Hagenbeek A, Arkesteyn GJA, Ying Y, Martens ACM: Minimal residual disease in acute leukemia (abstract 647). Exp Hematol 1990;18:718

    Google Scholar 

  67. Kedar E, Klein E: Cancer immunotherapy. Why clinical trials are discouraging —Can they be improved? Adv Cancer Res, in press.

  68. Allavena P, Grandi M, Incalci MD, Geri O, Giuliani FC, Mantovani A: Human tumor cell lines with pleiotropic drug resistance are efficiently killed by interleukin-2 activated killer cells and by activated monocytes. Int J Cancer 1987;40:104–107.

    Article  PubMed  CAS  Google Scholar 

  69. Salmon SE, Soehnlen B, Dalton WS, Melzer P, Scuderi P: Effects of tumor necrosis factor on sensitive and multidrug resistant human leukemia and myeloma cell lines. Blood 1989; 74:1723–1727.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Oncology, Department of Pediatrics, University of Parma, Italy

    Anna Butturini & Robert Peter Gale

  2. Division of Hematology and Oncology, Department of Medicine, University of California, 90024-1678, Los Angeles, Calif., USA

    Anna Butturini & Robert Peter Gale

Authors
  1. Anna Butturini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert Peter Gale
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Butturini, A., Gale, R.P. Graft versus leukemia. Immunol Res 11, 24–33 (1992). https://doi.org/10.1007/BF02918605

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02918605

Keywords

Search

Navigation